YOLFTbeta
Taysha Gene Therapies Inc

Taysha Gene Therapies Inc

TSHA · NASDAQ · Healthcare / Biotechnology

4.10USD-0.11 (-2.61%)

Price History

Full chart

Market Stats

Previous Close4.21
Open4.24
Day Range3.98 – 4.33
52-Week Range3.10 – 7.30
Volume2.47M
Market Cap1.52B
P/E (TTM)0.00
Forward P/E0.00
EPS-0.41
Dividend Yield0.00%
Beta1.17
50-Day Avg5.73
200-Day Avg5.48

About

Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; and TSHA-114 for the treatment of fragile X syndrome. The company has research, collaboration, and license agreement with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Sean P. Nolan
  • Employees99
  • Headquarters3000 Pegasus Park Drive, Dallas, TX, United States, 75247, USA
  • Websitehttps://www.tayshagtx.com

Leadership

  • Mr. Sean P. NolanCEO & Chairman · b. 1968
  • Dr. Sukumar Nagendran M.D.President, Head of Research & Development and Director · b. 1967
  • Mr. Kamran Alam CPA, M.B.A.CFO & Corporate Secretary · b. 1978
  • Hayleigh CollinsDirector of Corporate Communications & Investor Relations
  • Mr. Michael B. JohannesenChief Legal Officer & Corporate Secretary · b. 1966
  • Mr. Frederick Porter Ph.D.Chief of Staff & Technical Operations Officer
  • Ms. Emily McGinnis M.P.H.Chief Patient & External Affairs Officer
  • Mr. Sean McAuliffeChief Business Officer
  • Dr. Steven Gray Ph.D.Chief Scientific Advisor of UT Southwestern Gene Therapy Program
  • Berge Minassian M.D.Chief Medical Advisor of UT Southwestern Gene Therapy Program

Financials

Income Statement

Currency: USD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue-002.50M15.45M8.33M9.77M
Growth (%)----+517.55%-46.07%+17.28%
Cost of Revenue-9.00K492.00K2.49M1.37M1.25M1.15M
Gross Profit--9.00K-492.00K15.00K15.45M8.33M9.77M
Gross Margin---0.60%100.00%100.00%100.00%
Operating Expense-42.99M172.78M126.04M87.89M99.79M120.27M
Operating Income-1.11M-43.00M-173.27M-126.03M-72.44M-91.46M-110.50M
Operating Margin----5037.05%-468.83%-1097.55%-1130.65%
EBITDA-1.11M-59.97M-172.60M-159.73M-105.20M-87.95M-107.79M
EBITDA Margin----6384.05%-680.84%-1055.45%-1102.91%
Net Income-1.11M-43.00M-174.52M-166.01M-111.57M-89.30M-109.00M
Net Income Margin----6635.25%-722.06%-1071.62%-1115.27%
R&D987.00K31.89M131.94M91.17M56.78M66.00M86.40M
R&D as % of Total Revenue---3643.84%367.47%792.04%884.10%
Interest Expense028.00K1.43M3.80M5.00M102.00K63.00K
Interest Expense % of Total Revenue---151.80%32.35%1.22%0.64%

Balance Sheet

Currency: USD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets15.00K258.88M213.96M126.28M172.73M160.36M343.32M
Total Liabilities150.00K7.58M118.57M125.33M97.79M88.84M96.38M
Total Equity-135.00K251.30M95.38M949.00K74.94M71.53M246.94M
Cash-251.25M149.10M87.88M143.94M139.04M319.77M
Total Debt--63.09M59.93M61.11M63.18M18.17M
Net Debt--251.25M-86.01M-27.95M-82.83M-75.86M-301.60M

Cash Flow

Currency: USD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow135.00K-30.73M-117.04M-88.39M-73.02M-81.22M-93.09M
Investing Cash Flow-9.08M-9.08M-21.55M-24.93M-7.35M-363.00K-604.00K
Financing Cash Flow291.06M291.06M39.08M52.10M136.39M76.68M274.59M
Capital Expenditure82.00K9.08M21.55M24.87M7.37M374.00K738.00K
Free Cash Flow135.00K-39.81M-138.60M-113.26M-80.39M-81.60M-93.83M
FCF to OCF100.00%129.56%118.42%128.14%110.09%100.46%100.79%

Earnings

Report DateSep 25, 2020Nov 12, 2020Mar 3, 2021May 11, 2021Aug 16, 2021Nov 10, 2021Mar 31, 2022May 16, 2022Aug 11, 2022Nov 8, 2022Mar 28, 2023May 11, 2023Aug 14, 2023Nov 14, 2023Mar 19, 2024May 14, 2024Aug 12, 2024Nov 13, 2024Feb 26, 2025May 15, 2025Aug 12, 2025Nov 4, 2025Mar 4, 2026May 6, 2026Aug 11, 2026Nov 3, 2026
EPS Estimate-1.280.07-0.37-0.65-0.86-1.09-1.25-1.10-1.06-0.82-0.33-0.38-0.31-0.17-0.11-0.09-0.10-0.09-0.08-0.08-0.07-0.09-0.10-0.10-0.11-0.14
EPS Actual-1.28-1.28-1.04-0.87-1.09-1.35-1.32-1.31-0.84-0.64-0.99-0.28-0.38-0.930.92-0.10-0.09-0.07-0.07-0.08-0.08-0.09-0.07-0.11-0.13-
Surprise0.00%-1928.57%-181.08%-33.85%-26.74%-23.85%-5.60%-19.09%20.75%21.95%-200.00%26.32%-22.58%-447.06%936.36%-11.11%10.00%22.22%12.50%0.00%-14.29%0.00%23.43%-10.00%-18.18%-
TimingAfter-hoursAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-market-Pre-marketAfter-hours-

Key Statistics & Ratios

Market Cap1.52B
Enterprise Value1.20B
Trailing P/E0.00
Forward P/E0.00
Price / Sales277.42
Price / Book4.13
EPS-0.41
Book Value0.738
Revenue (TTM)5.49M
Gross Profit (TTM)5.49M
EBITDA-151.99M
Profit Margin0.00%
Operating Margin-2792.33%
Return on Equity-47.06%
Return on Assets-23.82%
Shares Outstanding325.83M
Shares Float232.62M
Beta1.17
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 10 analystsTarget 13.00
  • Strong Buy
    7
  • Buy
    3

Ownership Breakdown

Institutions
94.03%
Insiders
9.45%
Retail / Other
0.00%

Top Institutional Holders

  • RA Capital Management, LLC
    23.56M7.25%
  • The Goldman Sachs Group Inc
    22.37M6.89%
  • venBio Select Advisor LLC
    21.70M6.68%
  • BlackRock Inc
    18.37M5.65%
  • Vestal Point Capital LP
    18.00M5.54%
  • Morgan Stanley - Brokerage Accounts
    17.97M5.53%
  • FMR Inc
    14.32M4.41%
  • RTW INVESTMENTS, LLC
    13.68M4.21%
  • State Street Corp
    11.21M3.45%
  • Vanguard Capital Management, LLC
    10.23M3.15%
  • Octagon Capital Advisors LP
    9.69M2.98%
  • Siren, L.L.C.
    8.83M2.72%
  • Polar Capital Holdings PLC
    5.65M1.74%
  • Geode Capital Management, LLC
    5.53M1.70%
  • MPM Oncology Impact Management LP
    4.50M1.39%
  • D. E. Shaw & Co LP
    4.40M1.35%

Top Fund Holders

  • Vanguard MStar Total Stk Mkt Idx Invest
    9.17M2.82%
  • iShares Russell 2000 ETF
    6.15M1.89%
  • State Street® SPDR® S&P® Biotech ETF
    5.87M1.81%
  • Polar Capital Biotech S Inc
    4.85M1.49%